🔴 Capricor Therapeutics is trading 5.16% down today amid biotech-sector weakness

Capricor Therapeutics is trading 5.16% down at $7.57 amid a 2.47% drop in biotech stocks and broader market weakness as Treasury yields rise.

• It followed a sharp recent rebound, including a 12.71% gain on August 19 and a 57.96% jump on August 14.
• The unresolved regulatory overhang remains important: an FDA advisory committee voted 9-3 against deramiocel’s cardiomyopathy effectiveness.
• Capricor is pursuing a revised skeletal-muscle-focused strategy ahead of the August 22 FDA decision.